Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
Christopher T RitchlinPhilip S HelliwellWolf-Henning BoehnckeEnrique Roberto SorianoElizabeth C HsiaAlexa P KollmeierSoumya D ChakravartyFederico ZazzettiRamanand A SubramanianXie L XuQing C ZurawShihong ShengYusang JiangPrasheen AgarwalBei ZhouYanli ZhuangMay ShawiChetan S KaryekarAtul DeodharPublished in: RMD open (2021)
Guselkumab provided sustained improvement across multiple clinical manifestations of PsA, maintaining a favourable benefit-risk profile, through 1 year regardless of prior TNFi exposure.